Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
Identifieur interne : 001740 ( PubMed/Checkpoint ); précédent : 001739; suivant : 001741Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
Auteurs : Philippe Damier [France] ; Constance Hammond ; Yeheskel Ben-AriSource :
- Clinical neuropharmacology [ 1537-162X ]
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Bumetanide, Sodium Potassium Chloride Symporter Inhibitors.
- drug therapy : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.
DOI: 10.1097/WNF.0000000000000114
PubMed: 26757306
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26757306Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</title>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hammond, Constance" sort="Hammond, Constance" uniqKey="Hammond C" first="Constance" last="Hammond">Constance Hammond</name>
</author>
<author><name sortKey="Ben Ari, Yeheskel" sort="Ben Ari, Yeheskel" uniqKey="Ben Ari Y" first="Yeheskel" last="Ben-Ari">Yeheskel Ben-Ari</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2016 Jan-Feb</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:26757306</idno>
<idno type="pmid">26757306</idno>
<idno type="doi">10.1097/WNF.0000000000000114</idno>
<idno type="wicri:Area/PubMed/Corpus">000215</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000215</idno>
<idno type="wicri:Area/PubMed/Curation">000214</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000214</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000214</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000214</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</title>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="3"><nlm:affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hammond, Constance" sort="Hammond, Constance" uniqKey="Hammond C" first="Constance" last="Hammond">Constance Hammond</name>
</author>
<author><name sortKey="Ben Ari, Yeheskel" sort="Ben Ari, Yeheskel" uniqKey="Ben Ari Y" first="Yeheskel" last="Ben-Ari">Yeheskel Ben-Ari</name>
</author>
</analytic>
<series><title level="j">Clinical neuropharmacology</title>
<idno type="eISSN">1537-162X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Bumetanide (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Sodium Potassium Chloride Symporter Inhibitors (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bumetanide</term>
<term>Sodium Potassium Chloride Symporter Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26757306</PMID>
<DateCreated><Year>2016</Year>
<Month>01</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>10</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-162X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>39</Volume>
<Issue>1</Issue>
<PubDate><MedlineDate>2016 Jan-Feb</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Clinical neuropharmacology</Title>
<ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</ArticleTitle>
<Pagination><MedlinePgn>57-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/WNF.0000000000000114</ELocationID>
<Abstract><AbstractText>Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damier</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hammond</LastName>
<ForeName>Constance</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ben-Ari</LastName>
<ForeName>Yeheskel</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Neuropharmacol</MedlineTA>
<NlmUniqueID>7607910</NlmUniqueID>
<ISSNLinking>0362-5664</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D049994">Sodium Potassium Chloride Symporter Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0Y2S3XUQ5H</RegistryNumber>
<NameOfSubstance UI="D002034">Bumetanide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002034" MajorTopicYN="N">Bumetanide</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049994" MajorTopicYN="N">Sodium Potassium Chloride Symporter Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>1</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>1</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>10</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26757306</ArticleId>
<ArticleId IdType="doi">10.1097/WNF.0000000000000114</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Provence-Alpes-Côte d'Azur</li>
</region>
<settlement><li>Marseille</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Ben Ari, Yeheskel" sort="Ben Ari, Yeheskel" uniqKey="Ben Ari Y" first="Yeheskel" last="Ben-Ari">Yeheskel Ben-Ari</name>
<name sortKey="Hammond, Constance" sort="Hammond, Constance" uniqKey="Hammond C" first="Constance" last="Hammond">Constance Hammond</name>
</noCountry>
<country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001740 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001740 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:26757306 |texte= Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26757306" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |